The article examines how recent changes in pharmaceutical reimbursement policies in Spain from 1996 to 2002 have impacted cost containment. Four main policies were implemented, including a negative list of excluded products, a reference pricing system, changes in pharmacies' payment system, and agreements between the government and industry. These policies were not well integrated with each other. The study evaluates the effects of these policies on the behavior of those involved in the pharmaceutical market.